Home

What is it?

Search

Filters

Use filters to refine the search results.

Current Filters:


New Filters:

Showing 5 out of a total of 5 results for community: Universitat Pompeu Fabra. (0.38 seconds)

Now showing items 1-5 of 5

Sort Options:
Results Per Page:
- 5
- 10
- 20
- 40
- 60
- 80
- 100

Mechanisms of acquired resistance to anti-EGFR therapies in squamous cell carcinoma

Guix Arnau, Marta, 1974- (Date of defense: 19-12-2017)
Targeted therapies against the Epidermal Growth Factor Receptor (EGFR) are useful to treat many human cancers such as non-small cell lung cancer, colorectal cancer and head and neck cancer. However, the efficacy of such ...
MET and epithelial to mesenchymal transition as novel targets in small cell lung cancer

Cañadas Castillo, Israel, 1984- (Date of defense: 25-06-2013)
Small cell lung carcinoma (SCLC) is a highly lethal disease due to its chemorefractory nature after first line treatment. The mechanisms to overcome this resistance have remained elusive to tackle up to date. MET is a ...
Acquired resistance to the anti-EFGR monoclonal antibody cetuximab in colorectal cancer

Dalmases Massegú, Alba, 1982- (Date of defense: 22-06-2012)
EGFR is a transmembrane tyrosine kinase receptor from the HER family which, upon ligand stimulation, activates different signaling pathways involved in tumorogenesis. EGFR can be targeted by monoclonal antibodies, as ...
PARP1 expression in breast cancer and effects of its inhibition in preclinical models

García Parra, Jetzabel, 1983- (Date of defense: 21-06-2012)
Breast cancer is the main cause of cancer death in women. Improved treatments, prevention programs and earlier detection are reducing the rate of death; however, there is still a high percentage of mortality by this cancer. ...
Cancer-associated fibroblasts and response to anti-HER2 monoclonal antibodies in breast cancer

Guardia Valenzuela, Cristina, 1990- (Date of defense: 19-12-2019)
El cáncer de mama HER2-positivo es un subtipo muy agresivo. El desarrollo de terapias anti-diana HER2, particularmente el anticuerpo monoclonal (Mab) trastuzumab, supuso una mejora significativa en el pronóstico de esta ...